Research Library — Page 119 | Reta Compare

3563 research articles. Page 119 of 143.

Articles

• How does Thymosin Alpha-1 influence hormonal aging and thymic involution?
• Can Thymosin Alpha-1 support tissue regeneration with age?
• Can Thymosin Alpha-1 reverse thymic involution in aging individuals?
• How does Thymosin Alpha-1 influence stem cell function with age?
• Does Tirzepatide provide long-term cost-effectiveness for diabetes management?
• Can Tirzepatide improve outcomes in obesity-related heart failure?
• Can Tirzepatide improve metabolic aging and insulin sensitivity in older adults?
• Can Tirzepatide improve muscle function in lipedema-related dynapenia?
• How does Tirzepatide influence stem cell function with age?
• How does Tirzepatide improve metabolic aging and insulin sensitivity?
• Can Tirzepatide enhance brown adipose tissue function for longevity?
• Can Tirzepatide enhance weight loss and diabetes management in aging populations?
• Can Tirzepatide improve outcomes in heart failure with preserved ejection fraction?
• Can Tirzepatide mitigate neurotoxicity in aging-related chemotherapy treatments?
• Exploring Quad-Agonist GLP Drugs: The Next Generation After Retatrutide
• Exploring Penta-Agonist Metabolic Peptides: The 5-Receptor Frontier
• The Pharmacology Behind Multi-Agonist GLP Drugs
• From Tirzepatide to Retatrutide and Beyond: A Pipeline Timeline
• Single-Molecule Multi-Agonists vs Combination Therapy: Pros and Cons
• Designing Quad-Agonist Drugs: Fundamentals of Peptide Engineering
• Receptor Selectivity Tuning in Multi-Agonist Peptides for Obesity and Metabolic Disorders
• Pharmaceutical Giants Race Toward Quad-Agonists in Obesity and Metabolic Drug Development
• Exploring the Quad-Agonist Combination of GLP-1, GIP, Glucagon, and Amylin
• GLP-1 + GIP + Glucagon + FGF21: Enhancing Fatty Liver Activity
• GLP-1 + GIP + Glucagon + PYY/Y2: Enhancing Satiety through Multi-Agonism